FDG positron emission tomography for evaluating breast cancer.
D054598:Blue Cross Blue Shield Insurance Plans; D001943:Breast Neoplasms / Q000473:pathology*; D018795:Device Approval; D005260:Female; D019788:Fluorodeoxyglucose F18; D006801:Humans; D019458:Insurance Coverage; D008207:Lymphatic Metastasis / Q000000981:diagnostic imaging; D009364:Neoplasm Recurrence, Local / Q000000981:diagnostic imaging; D009367:Neoplasm Staging; D017063:Outcome Assessment, Health Care; D013673:Technology Assessment, Biomedical; D014055:Tomography, Emission-Computed; D014481:United States; D014486:United States Food and Drug Administration
D019788:Fluorodeoxyglucose F18